Nextseed's next phase

Houston investment platform acquired, new partnership grows investor access

With the acquisition, Youngro Lee, co-founder and CEO of NextSeed, has been named the COO of Republic. Courtesy of NextSeed

A growing New York-based private investment platform has acquired Houston-based NextSeed, according to announcements from both companies.

Republic announced the acquisition Monday, November 16, and appointed Youngro Lee, co-founder and CEO of NextSeed, as Republic's new COO. It's the third acquisition for Republic this year. Fig, a gaming-focused platform, and Compound, a real estate-focused platform, both joined the Republic family, allowing investors access to other industries.

"The NextSeed acquisition is just the latest milestone for Republic as we deliver the most expansive platform of marketplace offerings and investment types for private investors globally," Republic CEO Kendrick Nguyen says in a release.

Lee founded NextSeed with CMO Abe Chu and CTO Bob Dunton six years ago following the passage of the JOBS Act in 2012, that allowed smaller investments from non-accredited investors. Since then, NextSeed has facilitated $20 million in investments from 25,000 members into 75 local businesses.

It's a pivotal moment for the private investment community as just two weeks ago the SEC announced changes to Regulation Crowdfunding that included raising the fundraising caps from $1.07 million to $5 million. Between the new regulations and the new Republic deal, investing on NextSeed's platform will grow in scale.

"Now, by partnering with Republic, we believe that we can achieve so much more together for our entire business and investor community," NextSeed's executive team says in an email to investors. "We have known and worked with the Republic team for over four years, as both firms tried to strengthen and grow this industry since the very beginning of this movement."

Republic's founders are alums from AngelList and have made Republic one of the top private investing platforms in the industry with around 1 million members and more than $200 million facilitated through individual and institutional investors, according to the email.

According to NextSeed's email to its investors, little will change on the platform for investors, aside from access to new deals from Republic and its subsidiaries. Additionally, NextSeed will maintain its headquarters in Houston and the deal marks Republic's entrance into Houston and Texas.

Trending News

Building Houston

 
 

Dr. Peter Hotez and Dr. Maria Elena Bottazzi have been recognized by Fast Company for their leadership in developing low-cost COVID vaccine. Photo courtesy of Texas Children's

This week, Fast Company announced its 14th annual list of Most Creative People in Business — and two notable Houstonians made the cut.

Dr. Peter Hotez and his fellow dean of the National School of Tropical Medicine at Baylor College of Medicine, Dr. Maria Elena Bottazzi, were named among the list for “open sourcing a COVID-19 Vaccine for the rest of the world.” The list, which recognizes individuals making a cultural impact via bold achievements in their field, is made up of influential leaders in business.

Hotez and Bottazzi are also co-directors for the Texas Children's Hospital's Center for Vaccine Development -one of the most cutting-edge vaccine development centers in the world. For the past two decades it has acquired an international reputation as a non-profit Product Development Partnership (PDP), advancing vaccines for poverty-related neglected tropical diseases (NTDs) and emerging infectious diseases of pandemic importance. One of their most notable achievements is the development of a vaccine technology leading to CORBEVAX, a traditional, recombinant protein-based COVID-19 vaccine.

"It's an honor to be recognized not only for our team's scientific efforts to develop and test low cost-effective vaccines for global health, but also for innovation in sustainable financing that goes beyond the traditional pharma business model," says Hotez in a statement.

The technology was created and engineered by Texas Children's Center for Vaccine Development specifically to combat the worldwide problem of vaccine access and availability. Biological E Limited (BE) developed, produced and tested CORBEVAX in India where over 60 million children have been vaccinated so far.

Earlier this year, the doctors were nominated for the 2022 Nobel Peace Prize for their research and vaccine development of the vaccine. Its low cost, ease of production and distribution, safety, and acceptance make it well suited for addressing global vaccine inequity.

"We appreciate the recognition of our efforts to begin the long road to 'decolonize' the vaccine development ecosystem and make it more equitable. We hope that CORBEVAX becomes one of a pipeline of new vaccines developed against many neglected and emerging infections that adversely affect global public health," says Bottazzi in the news release from Texas Children's.

Fast Company editors and writers research candidates for the list throughout the year, scouting every business sector, including technology, medicine, engineering, marketing, entertainment, design, and social good. You can see the complete list here

.

Trending News